Current stock page

Stock Analysis

Xenon Pharmaceuticals Inc. (XENE) Stock Analysis

Xenon Pharmaceuticals Inc. (XENE) stock analysis covering valuation, fundamentals, technical indicators, risk, AIQ Momentum, analyst catalysts, dividends, and the current AIQ Score.

XENE Stock Analysis Summary

Xenon Pharmaceuticals Inc. (XENE) currently has an AIQ Score of 49/100, indicating a bearish setup. Quality is the strongest factor at 68/100. Momentum is the weakest current factor at 33/100. Technical, fundamental, catalyst, dividend, and risk evidence should be read together at the latest market-close snapshot.

Updated Nov 13, 2026 · Market-close data

XENE at a Glance

Crawlable current metrics from the latest market-close stock snapshot.

MetricCurrent
Price$40.48
AIQ Score49/100
Overall ViewBearish
Technical Analysis ConsensusBuy
Market Cap$4.04B
P/E Ratio (TTM)-8.61
Forward P/E—
EPS (Q3 FY2026)-$1.11
Revenue (Q3 FY2026)$0
Dividend Yield (TTM)0.00%
Beta0.86
Volume607.68K
52-week range$33.38-$72.66
RSI 1454.92
50-Day SMA$41.13
200-Day SMA$52.28
Analyst Price Target$67.86
Next EarningsFeb 25, 2027
As of Nov 13, 2026 · Market close

XENEXenon Pharmaceuticals Inc.

Healthcare / Biotechnology

Relative Leader / Watch

Strong Relative Position

BearishEdge 8/10
$40.48−$0.52 (−1.26%)

Latest quote

  • Momentum
    33
  • Value
    —
  • Quality
    68
  • Risk resilience
    49
  • Sentiment
    —
algovestiq.comScore data as of Nov 13, 2026

XENE Stock Analysis Summary

Xenon Pharmaceuticals Inc. (XENE) currently has an AIQ Score of 49/100, indicating a bearish setup. Quality is the strongest factor at 68/100. Momentum is the weakest current factor at 33/100. Technical, fundamental, catalyst, dividend, and risk evidence should be read together at the latest market-close snapshot.

Updated Nov 13, 2026 · Market-close data
AIQ Composite Posture: Bearish

In a bearish regime, XENE has AIQ Score of 49/100 with Quality base of 68/100 and fading Momentum at 33/100. Wait for component alignment before adding exposure.

Signal Conflict Detected

Quality (68/100) leads while Momentum (33/100) lags. This cross-factor spread creates entry timing uncertainty.

Healthcare · -1.26% stock move · XENE classified in Biotechnology.

Current Evidence

BearishXENE is in a bearish AIQ regime; Quality is the strongest visible factor at 68/100.
Core coverage reflects visible evidence only

AlgovestIQ Evidence Summary

Current consensus, supporting evidence, recent changes, and what would strengthen or weaken the view.

Is XENE Bullish or Bearish Right Now?

XENE currently has a bearish overall setup. Quality is the strongest factor at 68/100, while Momentum is weakest at 33/100. The current evidence suggests a bearish setup.

Bull Case
  • - Quality is supportive at 68/100.
  • - Analyst target implies +67.63% upside from the latest quote.
  • - Technical consensus has more buy votes than sell votes (27 vs 13).
Bear Case
  • - Momentum is weak at 33/100.
  • - Risk Resilience is weak at 49/100.
  • - Price is -22.56% below its 200-day SMA.

Current Consensus

XENE's Technical Analysis Consensus is currently Buy, with 27 buy, 6 neutral, and 13 sell votes. XENE's 14-day RSI is 54.92, which places the stock in a neutral momentum range. XENE's beta is 0.86, indicating market sensitivity broadly in line with the market.

Signal Confidence
High agreement

What Changed in XENE?

The largest recent change in XENE is Momentum moving up by 4.0 points over the available 7-day comparison window. Quality remains the strongest visible factor.

AIQ Score
+0.0
Momentum
+4.0
Quality
-3.0
Risk
+0.0

What Would Change the XENE Outlook?

The current bearish outlook could improve if AIQ reaches 65 (Bullish), momentum recovers, earnings revisions strengthen, and price confirms a stronger trend above the 50-day and 200-day moving averages. It would weaken if AIQ falls below 50 (Bearish), price loses long-term moving-average support, analyst expectations deteriorate, or risk evidence worsens.

Bullish confirmation

AIQ 65+ (Bullish), RSI above 55, price above SMA-50/SMA-200, and positive catalyst or estimate-revision evidence.

Bearish deterioration

AIQ below 50 (Bearish), RSI below 45, loss of SMA-200, negative revisions, or rising volatility and drawdown risk.

XENE Decision Framework

Public evidence layers, setup checks, and risk context for Xenon Pharmaceuticals Inc..

Xenon Pharmaceuticals Inc. (XENE) Stock Analysis

Xenon Pharmaceuticals Inc. has an AIQ Score of 49/100 in a Bearish regime. Quality is strongest at 68/100. Beta is 0.86, below market sensitivity. Review the supporting stock factors together before drawing a conclusion from any single score.

Evidence LayerPublic Evidence
Regime ContextXENE is in a Bearish AIQ regime with score 49/100.
Signal ConflictThe primary conflict is that quality leads at 68/100 while momentum lags at 33/100.
Factor EvidenceMomentum 33/100 · Quality 68/100 · Risk 49/100
PersistenceCurrent snapshot evidence is shown; historical persistence remains in AIQ Pro.

Current Setup Checklist

Factor strengthPass

Quality is the strongest factor at 68/100.

TimingFail

Momentum is 33/100 and RSI (14) is 54.9.

Regime fitFail

XENE is in a Bearish regime at 49/100.

Risk controlFail

Risk factor is 49/100 with beta 0.86 and annual volatility 68.13%.

ConflictWait

Current conflict: quality leads at 68/100 while momentum lags at 33/100.

AIQ Score
49/100
Price
$40.48
Beta
0.86
RSI (14)
54.9

XENE Research Cluster

Ticker-specific paths for valuation, technical analysis, catalysts, dividends, financials, risk, and news.

XENE Fundamentals

XENE valuation, profitability, growth, margins, balance-sheet strength, and free cash flow.

Revenue
$0
Net income
-$110.44M
Free cash flow
-$90.61M
View full XENE fundamental analysis

XENE Technical Analysis

XENE technical setup based on RSI, MACD, moving averages, AIQ Momentum, volume, trend, volatility, and pivots.

Technical Analysis Consensus
Buy
RSI 14
54.92
Price vs SMA-50
-1.58%
View full XENE technical analysis

XENE Stock Catalysts

Track XENE earnings, analyst ratings, price targets, estimate revisions, stock news, and upcoming events.

Next earnings
Feb 25, 2027
Analyst target
$67.86
News items
2
View XENE earnings and stock catalysts

XENE Dividend Analysis

XENE dividend yield, annual dividend, payout ratio, payment history, and income reliability context.

Dividend yield
0.00%
Annual dividend
—
Payout ratio
—
View XENE dividend history and analysis

XENE Financial Data

XENE revenue, earnings, income statement, balance sheet, cash flow, valuation ratios, and stock metrics.

Quarter revenue
$0
EPS
-$1.11
Periods
8
View XENE financials

XENE Risk Analysis

XENE volatility, beta, drawdown, Sharpe ratio, VaR, and downside resilience.

Beta
0.86
Risk score
49/100
1Y volatility
68.13%
View XENE risk analysis

XENE Stock News

XENE stock news, market tone, recent headlines, and catalyst context.

News items
2
Updated
Nov 15, 2026
Sentiment
—
Read XENE stock news

XENE vs Biotechnology Peers

Current peer cohort: XENE · XERS · ZBIO · ZYME · ABCL. Compare AIQ, factor scores, Sharpe ratio and 1-year volatility in one indexable view.

PeerAIQValueMomentumRiskSharpe1Y VolatilityCompare
XENE
Current stock
49/100—33/10049/1000.2768.13%Current
XERS
Xeris Biopharma Holdings, Inc.
78/10068/10098/10055/1001.6756.97%XENE vs XERS
ZBIO
Zenas BioPharma, Inc.
47/10033/10078/10039/1000.2695.33%XENE vs ZBIO
ZYME
Zymeworks Inc.
68/10066/10078/10061/1000.8454.03%XENE vs ZYME
ABCL
AbCellera Biologics Inc.
64/10047/10089/10034/1001.7385.28%XENE vs ABCL
Pairwise Compare links: XERS · ZBIO · ZYME · ABCLXENE vs XERSXENE vs ZBIOXENE vs ZYMEXENE vs ABCLCompare cohort

Peer cohort is resolved dynamically from the AlgovestIQ universe taxonomy and Compare relationship graph. Data as of Nov 13, 2026.

About the AIQ Score

Methodology for the current stock evidence.

As of Nov 13, 2026 · Market close

The AlgovestIQ AIQ Score combines multiple dimensions of stock evidence, including momentum, valuation exposure, quality, risk resilience, sentiment context, and timing signals. It is a descriptive research score, not a guarantee of future performance or a personalized recommendation.

View AIQ methodology

Factor Diagnostics

A compact bridge from the AIQ score to the evidence tabs.

Calculator
Calculate a XENE stock return scenario

Open the return calculator with stock context while purchase price, shares, dates and fees remain user inputs.

Calculate stock return

Also for XENE: historical return with reinvested dividends and stock average calculator for several buys.

AIQ Component Profile

Compare the five component scores on one consistent 0–100 scale.

Catalyst preview

Review earnings timing, revisions, news pressure, and prior event reactions in one place.

Open catalysts
Quarterly evidence

8 recent quarterly periods are available for review.

Checked Nov 16, 2026

AIQ Pro

Explore factor drivers, conflicts, persistence, and scenario sensitivity in the advanced workspace.

Fundamentals Verdict

Current snapshot fields are separate from reported-quarter statement tables.

Current TTM P/E
-8.61
As of Nov 13, 2026
Revenue growth
—
Gross margin
0.00%
Current debt / equity
0.01
Latest quarterly evidence

Latest period Sep 30, 2026.

Review fundamentals
Quarter revenue
$0
Quarter net income
-$110.44M
Quarter free cash flow
-$90.61M

Market Confirmation

Technicals are summarized first, with the indicator library behind it.

Trend
Bearish
Momentum
Mixed
RSI 14
54.92
MACD
0.28

Risk Alignment

Higher resilience is stronger; exposure metrics stay separate.

Resilience
49/100
Beta
0.86
Annual volatility
68.13%
Max drawdown
-52.80%

XENE Stock FAQ

What is XENE stock price today?

Xenon Pharmaceuticals Inc.'s current stock price is $40.48. Use the live quote with AIQ Score, news, and risk context rather than treating price alone as a decision signal.

Is XENE bullish or bearish right now?

XENE's bullish or bearish read depends on the current AIQ Score, factor alignment, technical analysis consensus, valuation, risk, and catalyst evidence. A mixed setup should be treated differently from a broad confirmation across those signals.

What is XENE's market cap?

XENE's market cap is $4.04B based on the latest completed market-close snapshot from Nov 13, 2026. Use it with P/E ratio, revenue, and growth metrics to frame company size, valuation, and peer comparisons.

What is XENE's current P/E ratio?

XENE's current P/E ratio is -8.61 based on the latest completed market-close snapshot from Nov 13, 2026. Read it with revenue growth, margins, EPS, cash flow, and peer valuation rather than using P/E alone.

What is XENE's RSI?

XENE's 14-day RSI is 54.92 based on the latest completed market-close snapshot from Nov 13, 2026. RSI should be interpreted with MACD, moving averages, volume, volatility, and price trend.

Is XENE above its 50-day and 200-day moving averages?

XENE is -1.58% from its 50-day SMA and -22.56% from its 200-day SMA based on the latest completed market-close snapshot from Nov 13, 2026. Moving-average position should be read with momentum and broader AIQ evidence.

When is XENE's next earnings date?

XENE's next earnings date is currently listed as Feb 25, 2027. Earnings can reset revenue, EPS, price target, analyst rating, and catalyst expectations.

Does XENE pay a dividend?

XENE's dividend yield is 0.00% based on the latest completed market-close snapshot from Nov 13, 2026. Dividend yield should be read with payout ratio, free cash flow, growth, and balance-sheet strength.